United States set
Menu Shopping cart $0 Search
Manufactured by BioVendor

sInterleukin-6 Receptor Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Other names:IL-6, Interferon-beta 2, B-cell stimulatory factor 2,HGF
  • Species:Human
Cat. No. Size Price

RAF107R 96 wells (1 kit) $721,88
PubMed Product Details
Technical Data


Sandwich ELISA, HRP-labelled antibody


Serum, Plasma-EDTA, Plasma-Heparin, Urine, Amniotic fluid, Cell culture supernatant, COVID-19

Sample Requirements

20 µl (1:50 prediluted)


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.08–5 ng/ml

Limit of Detection

0.01 ng/ml

Intra-assay (Within-Run)

CV = 1.7%

Inter-assay (Run-to-Run)

CV = 2.2%

Spiking Recovery


Dilution Linearity



Research topic

Cytokines and chemokines and related molecules, Energy metabolism and body weight regulation, Sepsis, COVID-19


Interleukin-6 (IL-6) is a multifunctional cytokine involved in the regulation of the immune response, hematopoiesis and acute phase response. It has been recognized to be a member of the a-helical cytokine family.
IL-6 exerts its action via a cell surface receptor which consists of two subunits, an 80 kDa ligand binding subunit (gp80) of 468 amino acids and a 130 kDa signal transducing protein (gp130) of 896 amino acid residues. The cDNAs of both proteins have been cloned. Both subunits belong to the recently recognized hematopoietic receptor superfamily which includes many cytokine receptors. Characterisation of the extracellular portion of the 80 kDa IL-6 receptor revealed the existence of a single immunoglobulin-like domain in the NH2-terminal of the extracellular region, which does not contribute to ligand binding. The remainder of the extracellular domain however is essential for low affinity ligand binding, which consecutively triggers the association of the receptor and gp130 thus forming a high affinity binding site for IL-6. For many cytokine receptors soluble forms have been demonstrated. These soluble molecules have been observed to retain ligand binding capacity and therefore compete with the membrane receptors, thus acting as antagonists. A soluble form of the Human gp80 protein has been detected in serum and urine samples. This 55 kDa protein representing the extracellular portion of gp80 is generated by shedding, a process that seems to be controlled by protein kinase C. It is still functional, indicating that soluble gp80 plays a biological role in promoting IL-6 activity. So far, the soluble IL-6 receptor is unique in acting as an agonist together with its ligand.
The role of soluble IL-6R as a marker for a number of pathological situations has been demonstrated.

Summary References (7)

References to Interleukin-6

  • Cayphas S, Van Damme J, Vink A, Simpson RJ, Billiau A, Van Snick J. Identification of an interleukin HP1-like plasmacytoma growth factor produced by L cells in response to viral infection. J Immunol. 1987 Nov 1;139 (9):2965-9
  • Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol Today. 1990 Dec;11 (12):443-9
  • Hirano T, Kishimoto T. Interleukin-6.Handbook of experimental pharmacology, Peptide Growth Factors and Their Receptors. Springer-Verlag. 1990;:633-665
  • Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu K, Nakajima K, Pyun KH, Kishimoto T. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A. 1985 Aug;82 (16):5490-4
  • Koj A. The Role of Interleukin-6 as the Hepatocyte Stimulating Factor in the Network of Inflammatory Cytokines. Annals of the New York Academy. (1989);:557: 1–8
  • Nordan RP, Potter M. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science. 1986 Aug 1;233 (4763):566-9
  • Ray A, Tatter SB, Santhanam U, Helfgott DC, May LT, Sehgal PB. Regulation of expression of interleukin-6. Molecular and clinical studies. Ann N Y Acad Sci. 1989;557:353-61; discussion 361-2
Related Products Docs